Endocrine Abstracts

Introduction: Hyperprolactinemia may be associated with weight gain, metabolic syndrome, and insulin resistance. Treatment with dopamine agonists (DA) has been shown to reduce body weight and improve metabolic parameters. The objective of our study is to confirm weight gain secondary to hyperprolactinemia and analyze the evolution of weight in patients under dopaminergic antagonists.

Materials and Methods: This is a prospective cross-sectional analytical study conducted over an 8-year period involving 88 patients aged ≥18 years, followed for prolactinomas who adhered to medical treatment with DA.

Results: The average age was 35 years, with most females (70.5%). The mean BMI was 28 kg/m², and the average abdominal waist circumference was 106 cm. The prevalence of overweight was 36.4%, and obesity was 34.1%. The average treatment duration was 6 years. Weight reduction was observed in 29.5% of patients.

Discussion and Conclusion: Patients with prolactinomas have a higher prevalence of obesity or overweight compared to normal individuals. The mechanism by which hyperprolactinemia induces weight gain is not fully understood, but the blockade of dopaminergic tone may play a significant role. Studies have shown that hyperprolactinemia affects the expression of genes involved in appetite regulation, contributing to increased fat mass in these patients. Normalizing prolactin levels can improve body composition. It is crucial to monitor BMI in patients with hyperprolactinemia and take measures to maintain an ideal weight and reduce the risks of associated diseases.